Literature DB >> 9449393

Baroreflex control of sympathetic nerve activity in essential and secondary hypertension.

G Grassi1, B M Cattaneo, G Seravalle, A Lanfranchi, G Mancia.   

Abstract

Studies performed in experimental animals and in humans have documented that high blood pressure markedly impairs baroreceptor control of heart rate. Whether a similar impairment also characterizes baroreceptor control of sympathetic activity modulating peripheral vasomotor tone is still unknown. In 28 untreated essential hypertensive subjects [14 of moderate and 14 of more severe degree, age 51.6+/-2.4 and 52.6+/-2.1 years (mean+/-SEM)] and in 13 untreated secondary hypertensives (renovascular or pheochromocytoma, age 50.1+/-4.6 years), we measured beat-to-beat arterial blood pressure (finger photoplethysmographic device), heart rate (electrocardiogram), and efferent postganglionic muscle sympathetic nerve activity (microneurography) at rest and during baroreceptor stimulation and deactivation induced by stepwise intravenous infusions of phenylephrine and nitroprusside, respectively. Data were compared with those obtained in 15 age-matched normotensive control subjects. Muscle sympathetic nerve activity (bursts per 100 heart beats) showed a progressive and significant (P<.01) increase from normotension (40.3+/-3.3) to moderate (55.6+/-4.1) and more severe essential hypertension (68.2+/-4.1), paralleling the progressive increase in blood pressure values. In contrast, muscle sympathetic nerve activity was not increased in secondary hypertensives (40.5+/-6.7) despite blood pressure values similar to or even greater than those of severe essential hypertensives. In both essential and secondary hypertensives, baroreceptor-heart rate control was displaced toward elevated blood pressure values and markedly impaired compared with normotensive subjects (average reduction, 38.5%). In contrast, the sympathoinhibitory and sympathoexcitatory responses to baroreceptor stimulation and deactivation were displaced toward elevated blood pressure values but similar in all groups. Thus, sympathetic activation characterizes essential but not secondary hypertension. Regardless of its nature, however, hypertension is not accompanied by an impairment of baroreceptor modulation of sympathetic activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9449393     DOI: 10.1161/01.hyp.31.1.68

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  105 in total

Review 1.  Sympathetic deactivation as a goal of nonpharmacologic and pharmacologic antihypertensive treatment: rationale and options.

Authors:  Guido Grassi
Journal:  Curr Hypertens Rep       Date:  2003-08       Impact factor: 5.369

Review 2.  Carotid baroreceptor activation for the treatment of resistant hypertension and heart failure.

Authors:  Michael Doumas; Charles Faselis; Costas Tsioufis; Vasilios Papademetriou
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

3.  Sympathetic nerves and the endothelium influence the vasoconstrictor effect of low concentrations of ouabain in pressurized small arteries.

Authors:  Hema Raina; Qingli Zhang; Albert Y Rhee; Thomas L Pallone; W Gil Wier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-09       Impact factor: 4.733

Review 4.  Catestatin: a multifunctional peptide from chromogranin A.

Authors:  Sushil K Mahata; Manjula Mahata; Maple M Fung; Daniel T O'Connor
Journal:  Regul Pept       Date:  2010-01-28

Review 5.  Functional neural-bone marrow pathways: implications in hypertension and cardiovascular disease.

Authors:  Jasenka Zubcevic; Monica M Santisteban; Teresa Pitts; David M Baekey; Pablo D Perez; Donald C Bolser; Marcelo Febo; Mohan K Raizada
Journal:  Hypertension       Date:  2014-03-31       Impact factor: 10.190

6.  Metaboreflex activation delays heart rate recovery after aerobic exercise in never-treated hypertensive men.

Authors:  Tiago Peçanha; Leandro Campos de Brito; Rafael Yokoyama Fecchio; Patricia Nascimento de Sousa; Natan Daniel da Silva Junior; Andrea Pio de Abreu; Giovanio Vieira da Silva; Décio Mion-Junior; Cláudia Lúcia de Moraes Forjaz
Journal:  J Physiol       Date:  2016-09-21       Impact factor: 5.182

7.  Social support and socioeconomic status interact to predict Epstein-Barr virus latency in women awaiting diagnosis or newly diagnosed with breast cancer.

Authors:  Christopher P Fagundes; Jeanette M Bennett; Catherine M Alfano; Ronald Glaser; Stephen P Povoski; Adele M Lipari; Doreen M Agnese; Lisa D Yee; William E Carson; William B Farrar; William B Malarkey; Min Chen; Janice K Kiecolt-Glaser
Journal:  Health Psychol       Date:  2011-10-17       Impact factor: 4.267

8.  Sympathetic genes, baroreflexes, and hypertension.

Authors:  Jens Jordan
Journal:  Clin Auton Res       Date:  2004-12       Impact factor: 4.435

Review 9.  The sympathetic nervous system alterations in human hypertension.

Authors:  Guido Grassi; Allyn Mark; Murray Esler
Journal:  Circ Res       Date:  2015-03-13       Impact factor: 17.367

10.  Cardiovascular responses to peripheral chemoreflex activation and comparison of different methods to evaluate baroreflex gain in conscious mice using telemetry.

Authors:  Valdir A Braga; Melissa A Burmeister; Ram V Sharma; Robin L Davisson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-07-30       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.